CNETS Canada is looking to gain insight into the Canadian neuroendocrine (NET) cancer patient experience with Gallium 68 scans to date. This information will assist us in developing next steps in our advocacy work in this area. We would really appreciate all NET cancer patients taking this survey, regardless of whether you have had a Gallium 68 scan or not.
The Gallium 68 (Ga68) scan, used with functional PET imaging, is another nuclear medicine scan that relies on the over-expression of somatostatin receptors to visualize tumours. NETs typically express several somatostatin receptor subtypes in a unique pattern based on tumour type, origin and grade of differentiation. Ga68 scans offer the advantages of improved image resolution and higher sensitivity. Tumours that may be visualized with a Ga68 scan include: gastroenteropancreatic (GEP) tumours; pheochromocytoma, paraganglioma, neuroblastoma, medullary thyroid carcinoma and others.
Your responses are anonymous and confidential. The information you provide will be consolidated and used in our communications to the various stakeholders who oversee access to and reimbursement of these scans in Canada. Most response fields are free text.
Please provide us with as much detail as you are comfortable sharing. This survey will be open until end of the day on Monday, October 17, 2016.
TAKE THE SURVEY <a href=”https://cnets.ca/?attachment_id=3025″ rel=”attachment wp-att-3025″>